Welcome to our dedicated page for United Therapeutics SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics EVP & General Counsel Paul A. Mahon exercised and sold company stock in a planned transaction. On June 18, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting 8,300 common shares in multiple open-market trades under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. The sales occurred at weighted-average prices generally in the mid-$530s to mid-$550s per share, as detailed in the trade price ranges.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 17, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the $548–$556 per share range.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of exercising up to 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists additional indirect holdings in United Therapeutics common stock through various family trusts and the reporting person’s spouse.
United Therapeutics Corporation notice of proposed sale of 8,300 shares of Common Stock pursuant to a Stock Option Exercise dated 06/18/2026. The filing lists multiple prior sales by the same holder on 03/19/2026 through 06/04/2026, each for 8,300 shares with reported gross proceeds shown in the filing.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 16, 2026, she exercised 9,500 stock options at $146.03 per share and acquired the same number of common shares.
Those 9,500 shares were then sold in multiple open-market trades at prices between $545.18 and $554.63 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these trades, she held 50,013 shares of common stock directly, plus additional indirect holdings through various family trusts and a small position of 166 shares held by her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting 9,500 shares of common stock. The options were exercised at an exercise price of $146.03 per share, and the shares were sold in multiple open-market transactions at prices generally in the mid-$540s per share.
According to the filing, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of the exercise of 1,734,410 stock options, all expiring on March 15, 2027, or December 31, 2026. The filing also reports additional indirect holdings in family trusts and by the CEO’s spouse.
United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales. On June 15, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share and converted those options into stock.
On the same date, he sold 10,000 shares of United Therapeutics common stock in multiple open-market transactions, at weighted average prices generally in the low-to-mid $500s per share, as detailed by price ranges in the footnotes. After these transactions, he directly owned 28,876 shares of common stock. The filing states that the option exercise and subsequent sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise of stock options and related share sales in a pre-planned transaction. On June 12, 2026, she exercised 9,500 stock options at a price of $146.03 per share and received the same number of common shares.
Those 9,500 common shares were then sold in multiple open-market trades at weighted average prices between roughly $539 and $546, under a Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 50,013 common shares directly and 40,910 stock options remain outstanding, expiring on March 15, 2027. Indirect holdings include common shares held through various family trusts and by her spouse, with reported positions of 8,902, 45,596, 249,108, 324,443, and 166 shares, respectively.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share, then sold 10,000 shares in multiple open-market trades on the same day under a Rule 10b5-1 trading plan. Following these transactions, he holds 18,876 shares of common stock directly.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, acquiring the same number of common shares.
That day, she sold 9,500 common shares in multiple open‑market trades at weighted average prices around $542–$552 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she holds 49,931 common shares directly, with additional shares held indirectly through family trusts and by her spouse.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported option-related trades in company common stock. She exercised 9,500 stock options at an exercise price of $146.03 per share and related open-market sales covered the same number of shares, resulting in a net sale of 9,500 shares according to the filing summary.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these transactions, Rothblatt directly holds 50,013 shares of common stock and 59,910 stock options, and also has additional indirect holdings through various family trusts and a spouse account.